Physician profile
Sharon E Martin
NPI 1891884375
$4,091.95
in general payments reported to CMS, 2019-2025
26 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $841 · 2021: $499 · 2022: $709 · 2023: $614 · 2024: $521 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,198.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $466.82 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $438.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.42 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $309.34 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $231.14 | 2023-2025 | |
| Daiichi Sankyo INC. | $214.83 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $179.08 | 2019-2022 | |
| Abbott Laboratories | $105.35 | 2022-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $90.15 | 2019-2024 | |
| Exact Sciences Corporation | $79.49 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $78.03 | 2019-2022 | |
| Astellas Pharma US INC | $77.58 | 2020-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $41.86 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.23 | 2022-2024 | Xifaxan, Trulance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.43 | 2019-2020 | |
| Amarin Pharma, INC. | $24.46 | 2021 | |
| Verona Pharma, INC. | $23.80 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $23.51 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $18.91 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $17.32 | 2025 | Rexulti |
| Genentech USA, INC. | $14.60 | 2020 | |
| Sanofi Pasteur INC. | $14.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.08 | 2023 | |
| Philips North America LLC | $13.03 | 2023 | |
| Bardy Diagnostics, INC. | $6.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.